Wedbush Reaffirms "Outperform" Rating for CytomX Therapeutics (NASDAQ:CTMX)

CytomX Therapeutics (NASDAQ:CTMX - Get Free Report)'s stock had its "outperform" rating reiterated by stock analysts at Wedbush in a research report issued on Monday,RTT News reports. They presently have a $6.00 price objective on the biotechnology company's stock, up from their prior price objective of $5.00. Wedbush's target price suggests a potential upside of 190.56% from the stock's previous close. Wedbush also issued estimates for CytomX Therapeutics' Q2 2025 earnings at ($0.14) EPS, Q3 2025 earnings at ($0.14) EPS, FY2025 earnings at ($0.33) EPS, Q1 2026 earnings at ($0.15) EPS, Q2 2026 earnings at ($0.18) EPS, Q3 2026 earnings at ($0.18) EPS, Q4 2026 earnings at ($0.19) EPS, FY2026 earnings at ($0.70) EPS, FY2027 earnings at ($0.66) EPS, FY2028 earnings at ($0.67) EPS and FY2029 earnings at $0.02 EPS.

Several other analysts have also commented on the stock. HC Wainwright reiterated a "neutral" rating on shares of CytomX Therapeutics in a research report on Friday, March 7th. Piper Sandler initiated coverage on shares of CytomX Therapeutics in a research note on Monday, April 14th. They set an "overweight" rating and a $2.50 price objective for the company. Finally, StockNews.com initiated coverage on shares of CytomX Therapeutics in a research report on Tuesday, April 15th. They issued a "hold" rating for the company.

CytomX Therapeutics Stock Down 13.2%

CTMX traded down $0.32 on Monday, reaching $2.07. The company had a trading volume of 6,134,194 shares, compared to its average volume of 2,052,997. The stock has a 50-day moving average price of $0.76 and a 200-day moving average price of $0.88. CytomX Therapeutics has a 1 year low of $0.40 and a 1 year high of $2.56. The stock has a market capitalization of $166.48 million, a PE ratio of 12.15 and a beta of 1.11.

CytomX Therapeutics (NASDAQ:CTMX - Get Free Report) last announced its quarterly earnings data on Monday, May 12th. The biotechnology company reported $0.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.18 by $0.09. The company had revenue of $50.92 million for the quarter, compared to analysts' expectations of $35.42 million. CytomX Therapeutics had a net margin of 10.96% and a negative return on equity of 41.47%. During the same period in the previous year, the company posted $0.17 EPS. As a group, analysts expect that CytomX Therapeutics will post -0.05 earnings per share for the current fiscal year.

Hedge Funds Weigh In On CytomX Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Traphagen Investment Advisors LLC acquired a new stake in shares of CytomX Therapeutics in the 4th quarter valued at $31,000. Miller Financial Services LLC bought a new stake in CytomX Therapeutics in the fourth quarter valued at about $26,000. Monimus Capital Management LP bought a new stake in CytomX Therapeutics in the fourth quarter valued at about $375,000. Prudential Financial Inc. grew its stake in CytomX Therapeutics by 76.2% during the fourth quarter. Prudential Financial Inc. now owns 64,300 shares of the biotechnology company's stock worth $66,000 after buying an additional 27,800 shares during the last quarter. Finally, JPMorgan Chase & Co. grew its stake in CytomX Therapeutics by 288,736.3% during the fourth quarter. JPMorgan Chase & Co. now owns 811,630 shares of the biotechnology company's stock worth $836,000 after buying an additional 811,349 shares during the last quarter. Institutional investors and hedge funds own 67.77% of the company's stock.

About CytomX Therapeutics

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.